Huge congrats to our research collaborators @KitePharma on their 2nd CAR T cell approval. Breakthrough for mantel cell lymphoma patients! We're incredibly fortunate to be working with them on next generation NK cell therapies
Big step forward (2 years ago) for the NK cell field when our now CEO and CSO first described a method for genetically modifying primary human NK cells with CRISPR RNP. Many targets have since been validated greatly expediting immunotherapy drug development #endcancer
Here at @oNKo_innate, we envisage unique NK cell therapies at different stages of cancer. Our CSO @Dr_Nick_Bikes recently presented his view of the NK cell - Cancer Immunity Cycle. With @GileadSciences @KitePharma we are developing novel NK cell immunotherapies to #endcancer
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
